High Purity 99% Etrasimod CAS 1206123-37-6
A novel selective S1P receptor modulator for ulcerative colitis treatment.
Get a Quote & SampleProduct Core Value
Etrasimod
Etrasimod is a groundbreaking oral, selective sphingosine 1-phosphate (S1P) receptor modulator designed for adult patients suffering from moderately to severely active ulcerative colitis. This advanced compound offers a novel approach to managing this chronic condition.
- Discover the benefits of Etrasimod CAS 1206123-37-6 for ulcerative colitis treatment. This selective S1P receptor modulator is specifically formulated to target the underlying mechanisms of the disease.
- Explore the therapeutic potential of this lymphocyte outflow blocker, which helps to reduce the migration of lymphocytes into the intestine, offering a new avenue for patient care.
- Understand the critical role of high purity pharmaceutical intermediates like Etrasimod in the development of effective medications for complex gastrointestinal disorders.
- Learn about Etrasimod's mechanism of action as a selective S1P receptor modulator, providing a targeted therapy for individuals with moderate to severe ulcerative colitis.
Advantages Offered by the Product
Selective S1P Receptor Modulation
Etrasimod offers a precise mechanism of action by selectively modulating S1P receptors, contributing to its efficacy in ulcerative colitis treatment.
Reduced Lymphocyte Migration
By acting as a lymphocyte outflow blocker, Etrasimod effectively reduces the number of lymphocytes in peripheral blood, a key factor in managing inflammatory bowel diseases.
High Purity and Quality
With 99% purity, this pharmaceutical intermediate ensures a high-quality input for drug manufacturing, vital for patient safety and therapeutic outcomes.
Key Applications
Ulcerative Colitis Management
Etrasimod is a key component in the advanced ulcerative colitis treatment, offering a targeted therapy for patients seeking relief from this challenging condition.
Inflammatory Bowel Disease Research
As a potent S1P receptor modulator, Etrasimod is crucial for ongoing research into inflammatory bowel diseases and their complex biological pathways.
Advanced Pharmaceutical Synthesis
This high-purity pharmaceutical intermediate is essential for the synthesis of sophisticated drug compounds, supporting innovation in medical treatments.
Immunomodulatory Therapies
The unique properties of Etrasimod, as a lymphocyte outflow blocker, position it as a critical agent in the development of next-generation immunomodulatory therapies.